Rohto Pharmaceutical Co Ltd
TSE:4527

Watchlist Manager
Rohto Pharmaceutical Co Ltd Logo
Rohto Pharmaceutical Co Ltd
TSE:4527
Watchlist
Price: 2 371.5 JPY -0.71% Market Closed
Market Cap: ¥560.1B

EV/EBIT

12.1
Current
19%
Cheaper
vs 3-y average of 15.1

Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBIT
12.1
=
Enterprise Value
¥489.9B
/
EBIT
¥40.2B

Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBIT
12.1
=
Enterprise Value
¥489.9B
/
EBIT
¥40.2B

Valuation Scenarios

Rohto Pharmaceutical Co Ltd is trading below its 3-year average

If EV/EBIT returns to its 3-Year Average (15.1), the stock would be worth ¥2 944.07 (24% upside from current price).

Statistics
Positive Scenarios
4/4
Maximum Downside
No Downside Scenarios
Maximum Upside
+28%
Average Upside
17%
Scenario EV/EBIT Value Implied Price Upside/Downside
Current Multiple 12.1 ¥2 371.5
0%
3-Year Average 15.1 ¥2 944.07
+24%
5-Year Average 15.5 ¥3 030.89
+28%
Industry Average 12.8 ¥2 501.04
+5%
Country Average 13.6 ¥2 663.44
+12%

Forward EV/EBIT
Today’s price vs future ebit

Not enough data available to calculate forward EV/EBIT

Peer Comparison

All Multiples
EV/EBIT
P/E
All Countries
Close
Market Cap EV/EBIT P/E
JP
Rohto Pharmaceutical Co Ltd
TSE:4527
535.9B JPY 12.1 15.5
FR
L'Oreal SA
PAR:OR
184.2B EUR 20.6 30.1
UK
Unilever PLC
LSE:ULVR
92B GBP 12.8 11.2
IN
Hindustan Unilever Ltd
NSE:HINDUNILVR
5.2T INR 40.4 38
UK
HALEON PLC
LSE:HLN
31.4B GBP 15.1 18.8
US
Estee Lauder Companies Inc
NYSE:EL
27.4B USD 22.5 -154.1
DE
Beiersdorf AG
XETRA:BEI
16.4B EUR 10.1 17.4
JP
Kao Corp
TSE:4452
2.7T JPY 15.1 22.6
IN
Godrej Consumer Products Ltd
NSE:GODREJCP
1.1T INR 41.9 63.7
CA
Relevium Technologies Inc
XTSX:RLV
12.2B CAD -6 360.4 -4 624.4
IN
Dabur India Ltd
NSE:DABUR
783.4B INR 39.3 43.8
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
JP
Rohto Pharmaceutical Co Ltd
TSE:4527
Average EV/EBIT: 23
12.1
N/A N/A
FR
L'Oreal SA
PAR:OR
20.6
7%
2.9
UK
Unilever PLC
LSE:ULVR
12.8
4%
3.2
IN
Hindustan Unilever Ltd
NSE:HINDUNILVR
40.4
8%
5.1
UK
HALEON PLC
LSE:HLN
15.1
8%
1.9
US
Estee Lauder Companies Inc
NYSE:EL
22.5
26%
0.9
DE
Beiersdorf AG
XETRA:BEI
10.1
4%
2.5
JP
Kao Corp
TSE:4452
15.1
N/A N/A
IN
Godrej Consumer Products Ltd
NSE:GODREJCP
41.9
13%
3.2
CA
Relevium Technologies Inc
XTSX:RLV
Negative Multiple: -6 360.4 N/A N/A
IN
Dabur India Ltd
NSE:DABUR
39.3
11%
3.6
P/E Multiple
Earnings Growth PEG
JP
Rohto Pharmaceutical Co Ltd
TSE:4527
Average P/E: 29
15.5
6%
2.6
FR
L'Oreal SA
PAR:OR
30.1
13%
2.3
UK
Unilever PLC
LSE:ULVR
11.2
-6%
N/A
IN
Hindustan Unilever Ltd
NSE:HINDUNILVR
38
7%
5.4
UK
HALEON PLC
LSE:HLN
18.8
11%
1.7
US
Estee Lauder Companies Inc
NYSE:EL
Negative Multiple: -154.1 N/A N/A
DE
Beiersdorf AG
XETRA:BEI
17.4
6%
2.9
JP
Kao Corp
TSE:4452
22.6
10%
2.3
IN
Godrej Consumer Products Ltd
NSE:GODREJCP
63.7
18%
3.5
CA
Relevium Technologies Inc
XTSX:RLV
Negative Multiple: -4 624.4 N/A N/A
IN
Dabur India Ltd
NSE:DABUR
43.8
11%
4

Market Distribution

In line with most companies in Japan
Percentile
42nd
Based on 4 801 companies
42nd percentile
12.1
Low
0.1 — 9.8
Typical Range
9.8 — 18.1
High
18.1 —
Distribution Statistics
Japan
Min 0.1
30th Percentile 9.8
Median 13.6
70th Percentile 18.1
Max 414 821 439

Rohto Pharmaceutical Co Ltd
Glance View

Market Cap
560.1B JPY
Industry
Consumer products

Rohto Pharmaceutical Co Ltd., a company deeply rooted in the legacy of Japanese innovation, traces its beginnings to the late 19th century. Initially specializing in over-the-counter (OTC) medicines, it has adeptly expanded its reach to include skincare and healthcare products. The company’s journey from its inception was marked by a relentless pursuit of addressing the evolving needs of its consumer base, leveraging its expertise in pharmaceuticals and chemistry to create products that cater to health and wellness. Rohto's commitment to research and development has enabled it to pioneer unique formulations, effectively blending traditional practices with modern scientific advances. This strategy has allowed Rohto to establish a strong foothold not only in Japan but also in international markets, appealing to a broad demographic. The core of Rohto's business lies in its ability to commercialize its innovative solutions across various channels. The company generates revenue primarily through the sale of its diversified product lines, which include eye drops, dermatological creams, and other personal care products. Rohto’s strategic acquisitions and partnerships have also played a critical role in its growth, enabling it to expand its market presence and adapt to global health trends. The ability to anticipate and respond to consumer needs allows Rohto to maintain a robust product pipeline, ensuring consistent sales performance. Through its global distribution networks and focused marketing efforts, Rohto capitalizes on its brand reputation for quality and reliability, ensuring a steady stream of profits.

Intrinsic Value
2 162.98 JPY
Overvaluation 9%
Intrinsic Value
Price ¥2 371.5
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett